Previous 10 | Next 10 |
2024-03-15 09:34:33 ET DENVER, Colo., Mar 15, 2024 ( 247marketnews.com )- Geron Corporation (NASDAQ: GERN ) announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat, based on results from the ...
2024-03-15 08:59:41 ET Summary Geron's valuation may overestimate imetelstat's market impact for MDS, given FDA's moderate enthusiasm and efficacy concerns. FDA concerns include imetelstat's marginal efficacy, safety issues, and a non-significant improvement in patient outcomes. ...
2024-03-15 05:45:23 ET More on related stocks: Adobe Inc. (ADBE) Q1 2024 Earnings Call Transcript Ulta Beauty, Inc. (ULTA) Q4 2023 Earnings Call Transcript Adobe Earnings: 3 Key Areas To Focus On With The Release Adobe in charts: Digital media revenue climbs ...
FDA Oncologic Drugs Advisory Committee voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat based on results from the IMerge Phase 3 clinical trial There are significant unmet needs across key TD LR-MDS patient populations, including difficult-to-treat subgroups that are ...
2024-03-14 15:39:52 ET More on Geron Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Geron Corporation (GERN) Q4 2023 Earnings Call Transcript Geron's Ideal Situation Appears To Be Already Priced In Geron slips as FDA reviews blood ...
2024-03-12 11:00:48 ET More on Geron Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Geron Corporation (GERN) Q4 2023 Earnings Call Transcript Geron's Ideal Situation Appears To Be Already Priced In Seeking Alpha’s Quant Rati...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
2024-03-05 10:30:29 ET Summary Geron Corporation's lead candidate, imetelstat, is awaiting FDA approval for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes. The company reported a loss from operations of $19...
2024-02-28 11:45:15 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q4 2023 Earnings Call Feb 28, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q4 2023 Earnings Call Transcript
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...